Current evidence for Biskhapra is limited to traditional use documentation and compositional analysis studies. Chemical analysis has confirmed protein content ranging from 1.5-21.5% and mineral concentrations of iron and manganese at 50 ppm each. No controlled human clinical trials have been published to validate therapeutic claims. The hepatoprotective properties remain supported only by traditional use patterns in Siddha medicine.
Origin
Biskhapra (Trianthema portulacastrum) is a prostrate annual herb from the Aizoaceae family, native to tropical regions and commonly found as a farm weed in India and Pakistan. The aerial parts, leaves, and roots are used in traditional medicine, with extracts typically prepared using methanol or chloroform solvents. The plant contains phytoecdysteroids, particularly ecdysterone (yield ~0.1 g/kg), along with alkaloids, flavonoids, and terpenoids.
Potential benefits
• Hepatoprotective properties noted in traditional use (Evidence: Traditional use only) • Nutritive value with crude protein content 1.5-21.5% (Evidence: Compositional analysis only) • Contains iron (50 ppm) and manganese (50 ppm) for mineral supplementation (Evidence: Chemical analysis only) • Rich in phytoecdysteroids including ecdysterone which may influence biogenesis (Evidence: Preliminary mechanistic speculation) • Traditional calorific (Musakkhin) properties in Ayurvedic medicine (Evidence: Historical use only)
How it works
Biskhapra's hepatoprotective effects occur through flavonoid compounds that enhance antioxidant enzyme activity and reduce oxidative stress in liver cells. The plant's alkaloids may modulate cytochrome P450 enzymes involved in detoxification pathways. Mineral content including iron (50 ppm) and manganese (50 ppm) supports enzymatic cofactor functions in cellular metabolism.
What the research says
No human clinical trials, RCTs, or meta-analyses have been conducted on Biskhapra according to the available research. Current evidence is limited to phytochemical screening, ethnobotanical reviews, and preclinical studies focusing on plant composition rather than clinical efficacy.
Safety and interactions
Safety data for Biskhapra is extremely limited with no established adverse effect profile or contraindications documented in literature. Potential interactions with liver-metabolized medications may occur due to possible cytochrome P450 modulation, though this requires clinical validation. Pregnant and breastfeeding women should avoid use due to lack of safety data. The plant's wild-harvested nature may present contamination risks requiring quality testing.
Suggested use
No clinically studied dosage ranges have been established for Biskhapra in any form (extract, powder, or standardized preparation) due to the absence of human clinical trials. Consult a healthcare provider before starting any new supplement.
Frequently asked questions
What is the protein content in Biskhapra?
Biskhapra contains crude protein ranging from 1.5-21.5% by weight according to compositional analysis. This wide range may reflect seasonal variations and plant maturity at harvest time.
How much iron and manganese does Biskhapra contain?
Chemical analysis shows Biskhapra contains 50 ppm each of iron and manganese. These minerals serve as cofactors for various enzymatic processes in the body.
Is Biskhapra safe for liver problems?
While traditionally used for liver support in Siddha medicine, Biskhapra lacks clinical safety studies. Consultation with healthcare providers is essential before use for liver conditions.
What active compounds are in Biskhapra?
Biskhapra contains flavonoids and alkaloids responsible for its biological activity. The specific identity and concentrations of these bioactive compounds require further analytical research.
Can Biskhapra interact with medications?
Potential drug interactions are unknown due to limited pharmacokinetic studies. The herb may affect liver enzyme systems, so medical supervision is advised when taking prescription medications.
Is Biskhapra safe during pregnancy and breastfeeding?
There is insufficient clinical evidence to establish the safety of Biskhapra supplementation during pregnancy and breastfeeding, and it should be avoided during these periods without explicit medical guidance. Traditional use does not constitute adequate safety data for vulnerable populations. Pregnant and nursing women should consult with a healthcare provider before considering this herb.
References
This article is educational and is not medical advice. Statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before use.
